Phase I Study of the Investigational Anti-Guanylyl Cyclase C (GCC) Antibody-Drug Conjugate (ADC) Mln0264 in Adult Patients with Advanced Gastrointestinal Malignancies Expressing GCC

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-15-2474 ◽

2016 ◽

Vol 22 (20) ◽

pp. 5049-5057 ◽

Cited By ~ 17

Author(s):

Khaldoun Almhanna ◽

Thea Kalebic ◽

Cristina Cruz ◽

Jason E. Faris ◽

David P. Ryan ◽

...

Keyword(s):

Phase I ◽

Guanylyl Cyclase ◽

Phase I Study ◽

Adult Patients ◽

Antibody Drug Conjugate ◽

Gastrointestinal Malignancies ◽

Drug Conjugate ◽

Mln0264, an Investigational, First-In-Class Antibody-Drug Conjugate Targeting Guanylyl Cyclase C (Gcc): First-In-Human Study in Patients with Advanced Gastrointestinal Malignancies

Annals of Oncology ◽

10.1093/annonc/mdt202.30 ◽

2013 ◽

Vol 24 ◽

pp. iv36 ◽

Cited By ~ 2

Author(s):

Wells Messersmith ◽

Khaldoun Almhanna ◽

Jordi Rodon ◽

Cristina Cruz ◽

David Ryan ◽

...

Keyword(s):

Guanylyl Cyclase ◽

Human Study ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Gastrointestinal Malignancies ◽

Drug Conjugate ◽

Class Antibody ◽

Abstract 3916: Relationship of guanylyl cyclase C (GCC) expression and efficacy of TAK-164, a GCC-targeted antibody-drug conjugate in a panel of 68 subcutaneous HuPrime colorectal cancer PDX models

10.1158/1538-7445.am2018-3916 ◽

2018 ◽

Cited By ~ 1

Author(s):

Erik M. Koenig ◽

Cong Li ◽

Huyuan Yang ◽

Andy Zhu ◽

Pooja Shah ◽

...

Keyword(s):

Colorectal Cancer ◽

Guanylyl Cyclase ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Relationship Of ◽

Pdx Models ◽

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-0711 ◽

2019 ◽

Vol 25 (23) ◽

pp. 6986-6994 ◽

Cited By ~ 19

Author(s):

Brad S. Kahl ◽

Mehdi Hamadani ◽

John Radford ◽

Carmelo Carlo-Stella ◽

Paolo Caimi ◽

...

Keyword(s):

Phase I ◽

B Cell ◽

Hodgkin Lymphoma ◽

Phase I Study ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).

10.1200/jco.2016.34.15_suppl.2511 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 2511-2511 ◽

Cited By ~ 15

Author(s):

Carlos Alberto Gomez-Roca ◽

Valentina Boni ◽

Victor Moreno ◽

John Charles Morris ◽

Jean-Pierre Delord ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

Investigational New Drugs ◽

10.1007/s10637-017-0439-y ◽

2017 ◽

Vol 35 (2) ◽

pp. 235-241 ◽

Cited By ~ 8

Author(s):

Khaldoun Almhanna ◽

Maria Luisa Limon Miron ◽

David Wright ◽

Antonio Cubillo Gracian ◽

Richard A. Hubner ◽

...

Keyword(s):

Phase Ii ◽

Guanylyl Cyclase ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma

Investigational New Drugs ◽

10.1007/s10637-019-00832-1 ◽

2019 ◽

Vol 38 (3) ◽

pp. 844-854 ◽

Cited By ~ 4

Author(s):

Shahneen Sandhu ◽

Catriona M. McNeil ◽

Patricia LoRusso ◽

Manish R. Patel ◽

Omar Kabbarah ◽

...

Keyword(s):

Phase I ◽

Uveal Melanoma ◽

Phase I Study ◽

Antibody Drug Conjugate ◽

Endothelin B Receptor ◽

Receptor Antibody ◽

Drug Conjugate ◽

Endothelin B ◽

A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC)

10.1200/jco.2008.26.15_suppl.1028 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 1028-1028 ◽

Cited By ~ 20

Author(s):

M. Beeram ◽

H. A. Burris ◽

S. Modi ◽

M. Birkner ◽

S. Girish ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Phase I Study ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Her2 Breast Cancer ◽

The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study.

10.1200/jco.2011.29.15_suppl.3071 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 3071-3071 ◽

Cited By ~ 5

Author(s):

J. A. Thompson ◽

A. Forero-Torres ◽

E. I. Heath ◽

S. M. Ansell ◽

S. K. Pal ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Hodgkin Lymphoma ◽

Renal Cell ◽

Phase I Study ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

Activity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on metastatic colorectal cancer (mCRC) having relapsed after CPT-11: Phase I study.

10.1200/jco.2014.32.15_suppl.3106 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 3106-3106 ◽

Cited By ~ 4

Author(s):

Efrat Dotan ◽

Jordan Berlin ◽

Alexander Starodub ◽

Michael J. Guarino ◽

Steven J. Cohen ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase I ◽

Metastatic Colorectal Cancer ◽

Phase I Study ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽